ContraVir Pharmaceuticals Announces $9.0 Million Private Placement
Sichenzia Ross Friedman Ference LLP Advises ContraVir Pharmaceuticals on $9.0 Million Private Placement
New York, October 28, 2014 (Global Newswire) – New York based securities law firm Sichenzia Ross Friedman Ference LLP announced that it has represented ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, on a $9 million private placement consisting of Series A Convertible Preferred stock to a non-U.S investor.
Pursuant to the private placement, the Series A Preferred Stock can be converted into shares of common stock at the conversion price of $0.48 per share. The Sichenzia Ross Friedman Ference LLP team was led by partner Jeffrey J. Fessler.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Advises US Gold Corp. on $2.5 Million Public Offering - October 13, 2017
- Sichenzia Ross Ference Kesner LLP Represents Pareteum Corporation in $1.56 Million Shelf Take Down - October 12, 2017
- Sichenzia Ross Ference Kesner LLP Cited as Top-Ranked Legal Counsel for PIPE Issuers in the Third Quarter 2017 - October 3, 2017